MTOR and B-cell chronic lymphocytic leukemia: These results and corresponding ex vivo treatment results with the dual PI3K/mTOR inhibitor NVP-BEZ235 help demonstrate the potential dependence of mRNA translation in CLL survival, as well as revealing mRNA translation as a potential therapeutic target in CLL.